Targeted Protein Degradation - Global Strategic Business Report

The global market for Targeted Protein Degradation was estimated at US$528.2 Million in 2024 and is projected to reach US$1.4 Billion by 2030, growing at a CAGR of 17.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Targeted Protein Degradation market.

Global Targeted Protein Degradation Market - Key Trends & Drivers Summarized

Why Is Targeted Protein Degradation Redefining Drug Discovery and Therapeutics?

Targeted protein degradation (TPD) has emerged as one of the most promising frontiers in drug discovery, offering a new paradigm in the way diseases - particularly those involving previously “undruggable” targets - can be treated. Unlike conventional small molecule inhibitors that merely block the active sites of proteins, TPD leverages the cell’s own protein degradation machinery to completely eliminate disease-causing proteins from the system. This mechanism offers the potential for deeper and longer-lasting therapeutic effects while expanding the druggable proteome beyond the limits of traditional pharmacology. Central to this approach are heterobifunctional molecules such as PROTACs (Proteolysis-Targeting Chimeras), molecular glues, and other novel modalities that induce selective degradation by recruiting E3 ubiquitin ligases to tag target proteins for proteasomal destruction. This method bypasses the need for a functional binding pocket and allows degradation of scaffolding proteins, transcription factors, and regulatory complexes - many of which are implicated in cancers, neurodegenerative diseases, and immune disorders. The therapeutic implications are profound, enabling researchers to revisit previously abandoned targets and explore new biological pathways. Pharmaceutical companies, biotech innovators, and academic institutions alike are pouring resources into this domain, seeing it not just as a tool, but as a revolutionary platform technology. As the first clinical-stage TPD therapies begin to show encouraging results, the field is poised to redefine the landscape of precision medicine and disease modification.

How Are Technological Innovations Driving the Evolution of TPD Modalities and Platforms?

The field of targeted protein degradation is being rapidly transformed by a wave of technological innovation, which is expanding the chemical diversity, delivery efficiency, and tissue specificity of TPD-based therapeutics. PROTACs, initially limited by size and bioavailability, are now being engineered with improved pharmacokinetics through linker optimization, macrocyclic scaffolds, and structure-guided design techniques. Meanwhile, molecular glues - small molecules that induce protein-protein interactions to promote ubiquitination - are gaining momentum due to their simpler structures and favorable drug-like properties. Advances in structural biology, including cryo-EM and NMR spectroscopy, are enabling a clearer understanding of ternary complex formation, a critical factor in the efficacy of degraders. New screening platforms, such as DNA-encoded libraries, CRISPR-based functional genomics, and high-content phenotypic assays, are helping identify degradable targets and match them with optimal E3 ligase partners. In parallel, tissue-specific ligases and targeted delivery systems are being developed to enhance safety profiles and expand TPD’s applicability beyond oncology. The use of antibody-drug conjugates (ADCs) and nanoparticle delivery vehicles for PROTACs is also under investigation, particularly for targeting the brain and other difficult-to-penetrate tissues. Artificial intelligence and machine learning tools are increasingly being applied to predict degrader efficacy and optimize compound design at scale. These innovations are rapidly converting TPD from an experimental concept into a multi-faceted platform capable of producing first-in-class and best-in-class therapeutics across a wide spectrum of diseases.

Where Is Targeted Protein Degradation Making the Strongest Clinical and Commercial Impact?

Targeted protein degradation is making its most immediate impact in the field of oncology, where many high-value targets - such as BRD4, BCL-XL, and androgen or estrogen receptors - have been successfully degraded in preclinical and early clinical studies. Several PROTAC-based drugs have entered human trials, including candidates targeting prostate cancer, breast cancer, and hematologic malignancies, often showing efficacy where traditional inhibitors have failed or encountered resistance. In addition to cancer, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS represent a major area of opportunity for TPD, given the involvement of misfolded, aggregated, or intrinsically disordered proteins that are difficult to inhibit but potentially degradable. Autoimmune and inflammatory diseases are also emerging targets, particularly as degraders are developed for cytokine modulators and intracellular immune regulators. The commercial landscape is expanding rapidly, with major pharmaceutical companies entering multi-billion-dollar partnerships with biotech firms that specialize in degrader discovery and optimization. Companies like Arvinas, Kymera Therapeutics, Nurix, and C4 Therapeutics are leading clinical development efforts and have established validated pipelines spanning various therapeutic areas. Beyond the clinical setting, academic research centers are increasingly adopting TPD tools to study protein function and cellular biology, further driving innovation. Geographically, North America dominates early-stage development and funding, but Europe and Asia-Pacific are ramping up investment, regulatory engagement, and institutional collaborations. As intellectual property portfolios grow and first-generation degrader drugs approach regulatory review, the commercial potential of TPD is becoming increasingly tangible, signaling a major shift in how drug pipelines may be shaped in the coming decade.

What’s Fueling the Rapid Growth of the Global Targeted Protein Degradation Market?

The growth of the global targeted protein degradation market is driven by a confluence of scientific breakthroughs, unmet clinical needs, investment momentum, and broadening therapeutic applications. One of the core drivers is the significant ability of TPD to access the large swath of disease-related proteins that have remained unaddressable by conventional small molecules and biologics. The promise of more complete and durable protein silencing makes it a highly attractive option for treating diseases characterized by protein overexpression or mutation-driven pathogenicity. Rising incidence of cancers and chronic illnesses globally is also pushing demand for more selective, resistance-evading therapies - an area where TPD has strong competitive advantage. The influx of venture capital and strategic pharmaceutical partnerships is accelerating pipeline development and pushing more candidates into clinical evaluation. Technological advancements in ligand discovery, linker chemistry, computational modeling, and high-throughput screening are increasing the speed and success rate of degrader development. Regulatory agencies are also showing interest in these novel mechanisms, offering fast-track designations and orphan drug incentives for certain programs, further supporting commercialization. Meanwhile, the growing availability of cell-permeable, orally bioavailable degraders is overcoming previous barriers to adoption. Academic research and early-access TPD toolkits are expanding awareness and enabling non-commercial R&D initiatives, fostering a richer discovery ecosystem. As combination therapies and tissue-specific degraders gain traction, and new E3 ligases are identified and harnessed, the market is set to expand rapidly - positioning targeted protein degradation as a core modality in the future of precision and systems-level therapeutics.

Report Scope

The report analyzes the Targeted Protein Degradation market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Type (PROTAC, Molecular Glues, LYTACs, Others); Application (Drug Discovery, Therapy Development); End-Use (Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Clinical Laboratories, Others)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the PROTAC segment, which is expected to reach US$598.8 Million by 2030 with a CAGR of a 20.8%. The Molecular Glues segment is also set to grow at 15.5% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $143.9 Million in 2024, and China, forecasted to grow at an impressive 24.8% CAGR to reach $334.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Targeted Protein Degradation Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Targeted Protein Degradation Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Targeted Protein Degradation Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Accutar Biotechnology, AION Labs, Amphista Therapeutics, Arvinas, Inc., Astellas Pharma Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 48 Featured):

• Accutar Biotechnology
• AION Labs
• Amphista Therapeutics
• Arvinas, Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Bio-Techne Corporation
• Bristol-Myers Squibb Company
• C4 Therapeutics, Inc.
• Captor Therapeutics
• Cullgen Inc.
• Draupnir Bio
• F. Hoffmann-La Roche Ltd
• GSK plc
• Halda Therapeutics
• Kymera Therapeutics, Inc.
• Lycia Therapeutics
• Merck KGaA
• Monte Rosa Therapeutics
• Novartis International AG
• Nurix Therapeutics, Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry